Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration

Thrombosis and Haemostasis

Volumn 104, Issue 1, 2010, Pages 23-29

  Boheler, Kenneth R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Development and disease; Embryonic stem cells; Heart; Induced pluripotent (iPS) stem cells; Vasculature

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANGIOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CONGENITAL HEART DISEASE; EMBRYONIC STEM CELL; HEART DISEASE; HUMAN; MUSCLE REGENERATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VASCULAR DISEASE;

AGING; ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; EMBRYONIC STEM CELLS; GUIDED TISSUE REGENERATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCARDIUM; STEM CELL TRANSPLANTATION;

EID: 77954353258     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-07-0507     Document Type: Review

References (62)

1. Pierpont ME, Basson CT, Benson DW, et al. Genetic basis for congenital heart defects: Current knowledge - A scientific statement from the American heart association congenital cardiac defects committee, council on cardiovascular disease in the young. Circulation 2007; 115: 3015-3038.
2. Najjar SS, Scuteri A, Lakatta EG. Arterial aging - Is it an immutable cardiovascular risk factor? Hypertension 2005; 46: 454-462.
3. Lakatta EG, Wang MY, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am 2009; 93: 583-604.
4. Chantler PD, Lakatta EG, Najjar SS. Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol 2008; 105: 1342-1351.
5. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102: 240-247.
6. Vanhoutte PM, Shimokawa H, Tang EHC, et al. Endothelial dysfunction and vascular disease. Acta Physiol 2009; 196: 193-222.
7. Vanhoutte PM. Endothelial dysfunction - The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
8. Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev 2005; 85: 635-678.
9. Yamanaka S, Li JL, Kania G, et al. Pluripotency of embryonic stem cells. Cell Tissue Res 2008; 331: 5-22.
10. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
11. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448: 313-317.
12. Zou JZ, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5: 97-110.
13. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007; 25: 1177-1181. (Pubitemid 47538112)
14. Boheler KR. Stem cell pluripotency: A cellular trait that depends on transcription factors, chromatin state and a checkpoint deficient cell cycle. J Cell Physiol 2009; 221: 10-17.
15. Perino MG, Yamanaka S, Li JL, et al. Cardiomyogenic stem and progenitor cell plasticity and the dissection of cardiopoiesis. JMolCellCardiol 2008; 45: 475-494.
16. Yamanaka S. A Fresh Look at iPS Cells. Cell 2009; 137: 13-17.
17. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872. (Pubitemid 350138099)
18. Huangfu DW, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
19. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
20. Stadtfeld M, Hochedlinger K. Without a trace? PiggyBac-ing toward pluripotency. Nat Methods 2009; 6: 329-330.
21. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced Pluripotent Stem Cells Generated Without Viral Integration. Science 2008; 322: 945-949.
22. Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H, Jaenisch R. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008; 2: 151-159. (Pubitemid 351168714)
23. Stadtfeld M, Maherali N, Breault DT, et al. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008; 2: 230-240.
24. Maherali N, Sridharan R, Xie W, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007; 1: 55-70.
25. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448: 318-324.
26. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009; 5: 111-123.
27. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26: 101-106.
28. Aoi T, Yae K, Nakagawa M, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321: 699-702.
29. Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Current Biol 2008; 18: 890-894.
30. Kim JB, Zaehres H, Wu GM, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454: 646-650.
31. Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 2008; 26: 2467-2474.
32. Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133: 250-264. (Pubitemid 351508307)
33. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26: 1276-1284.
34. Maherali N, Ahfeldt T, Rigamonti A, et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008; 3: 340-345.
35. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3: 595-605.
36. Gundry RL, Boheler KR, Van Eyk JE, et al. A novel role for proteomics in the discovery of cell-surface markers on stem cells: Scratching the surface. Proteom Clin Appl 2008; 2: 892-903.
37. Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418: 50-56. (Pubitemid 34742566)
38. Blyszczuk P, Czyz J, Kania G, et al. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci USA 2003; 100: 998-1003.
39. Choi K, Kennedy M, Kazarov A, et al. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-732.
40. Fehling HJ, Lacaud G, Kubo A, et al. Tracking mesoderm induction and its specification to the hemangioblast during embryonic stem cell differentiation. Development 2003; 130: 4217-4227.
41. Huber TL, Kouskoff V, Fehling HJ, et al. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 2004; 432: 625-630.
42. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. Cell 2008; 132: 661-680.
43. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997; 89: 981-990. (Pubitemid 27513524)
44. Kouskoff V, Lacaud G, Schwantz S, et al. Sequential development of hematopoietic and cardiac mesoderm during embryonic stem cell differentiation. Proc Natl Acad Sci USA 2005; 102: 13170-13175.
45. Kennedy M, D'Souza SL, Lynch-Kattman M, et al. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 2007; 109: 2679-2687. (Pubitemid 46482058)
46. Kofidis T, de Bruin JL, Hoyt G, et al. Myocardial restoration with embryonic stem cell bioartificial tissue transplantation. J Heart Lung Transpl 2005; 24: 737-744. (Pubitemid 40798258)
47. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112: I166-I172. (Pubitemid 41266669)
48. Kolossov E, Bostani T, Roell W, et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 2006; 203: 2315-2327.
49. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25: 1015-1024.
50. Li Z, Wu JC, Sheikh AY, et al. Differentiation, survival, and function of embryonic stem cell-derived endothelial cells for ischemic heart disease. Circulation 2007; 116: I46-I54.
51. Wang ZZ, Au P, Chen T, et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 2007; 25: 317-318.
52. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920-1923.
53. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008; 105: 5856-5861.
54. Nelson TJ, Martinez-Fernandez A, Yamada S, et al. Repair of Acute Myocardial Infarction by Human Stemness Factors Induced Pluripotent Stem Cells. Circulation 2009; 120: 408-416.
55. Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008; 118: 498-506.
56. Zhang JH, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. CircRes 2009; 104: E30-E41.
57. Tateishi K, He J, Taranova O, et al. Generation of Insulin-secreting Islet-like Clusters from Human Skin Fibroblasts. J Biol Chem 2008; 283: 31601-31607.
58. Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009; 106: 808-813.
59. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321: 1218-1221.
60. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
61. Menasche P. Stem cells for clinical use in cardiovascular medicine - Current limitations and future perspectives. Thromb Haemost 2005; 94: 697-701. (Pubitemid 41508726)
62. Fraidenraich D, Stillwell E, Romero E, et al. Rescue of cardiac defects in Id knockout embryos by injection of embryonic stem cells. Science 2004; 306: 247-252. (Pubitemid 39336864)